3 Things In Biotech, June 18: Some More Good Heme News!

|
Includes: ATRA, BGNE, BLRX
by: Zach Hartman
Summary

BioLineRx gives a favorable look at their heme transplant recovery treatment.

BeiGene updates on its BTK inhibitor program.

Atara glimpses strong results in its customized cell therapy.

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription?

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

BioLineRx gives a favorable look at their heme transplant recovery treatment

Company: BioLineRx (BLRX)

Therapy: BL-8040

Disease: Bone marrow transplantation

News: BLRX presented findings from its phase 2 study involving the CXCR4 antagonist BL-8040 in patients undergoing stem cell transplantation for blood cancer. The primary endpoint of the study was the rate of collecting a specific number of hematopoietic stem cells from donors. In all, 19 of the 21 patients who received one of two doses of BL-8040 achieved this endpoint. Donated bone marrow engrafted in a median of around 13 days, and the therapy was well tolerated overall.

Looking forward: These findings are promising for this stem cell mobilization technique, as currently donors have to undergo almost a week of treatment with a colony stimulating factor to help boost the number of stem cells they can donate. This is associated with significant potential toxicity and discomfort, and the potential life-threatening toxicity is unacceptable for patients who do not have cancer. The engraftment findings here suggest that BL-8040 achieves comparable results, but in a single dose of the agent, instead of over many days.

BeiGene updates on its BTK inhibitor program

Company: BeiGene (BGNE)

Therapy: Zanibrutinib

Disease: Various B-cell malignancies

News: BGNE provided an update on the development of their BTK inhibitor zanibrutinib, an agent analogous to ibrutinib and acalabrutinib, in the management of various heme malignancies. This coincided with data presentations at EHA describing the use of zanibrutinib in mantle cell lymphoma and Waldenstrom's macroglobulinemia. Patients experienced high response rates in both diseases. The company intends to submit its first marketing applications later this year in 2018 to the Chinese authorities.

Looking forward: I continue to feel strongly about BGNE as a company one will regret ignoring. Currently, they're taking a beating partly on the news that Bristol-Myers (NYSE:BMY) got their PD-1 drug approved in China, a first for the entire class. But they have a cache of drugs that have a strong chance of approval in a market largely untapped by Western pharmaceutical companies. These findings are continued signals that BGNE is going to achieve something special with their lines of agents from classes that have been used in America for years now.

Atara glimpses strong results in its customized cell therapy

Company: Atara Biotherapeutics (ATRA)

Therapy: Tabelecleucel

Disease: Epstein-Barr virus (EBV)-positive cancers

News: ATRA presented findings from a phase 1/2 study involving tabelecleucel in patients with rituximab-refractory EBV-positive lymphoma at EHA 2018. ATRA divulged that response rates ranged from 50% to 69% in lymphoma following hematopoietic cell transplantation or solid organ transplantation, respectively. In the latter patient group, median overall survival was 21.3 months, and this endpoint had not been reached in the patients with lymphoma after heme transplantation. In patients who achieved a response, over 80% were alive after 3 years.

Looking forward: These are important findings for a study addressing a major problem for patients. Viral reactivation can be a serious complication in these patients who need to undergo some form of substantial immunosuppression. However, as we know, certain viruses can cause cancer, as well, such as EBV. So we need as many treatment options as we can get. Cell therapy may be extremely well positioned to attack this problem, as the virus will make very specific antigens that can be targeted. This helps to explain the favorable results shown at EHA! I think this could be a signal for an important line of development for ATRA and tabelecleucel.

Author's note: Thank you for taking some time out of your day to read some commentary on recent biotech happenings. I hope you'll consider leaving a comment or a question in the section below! This is one way in which Seeking Alpha is able to gauge the effectiveness of its writers and the platform. So if you want to keep seeing more editions of "3 Things," go ahead and participate!

As I mentioned above, I am now collaborating with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. I will also collaborate in developing watchlists and other investment essentials. Please subscribe to TPT by clicking on this link - Total Pharma Tracker.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more microcap stocks. Please be aware of the risks associated with these stocks.